NZYM B Novozymes A/S Class B

Total number of voting rights and capital on January 31, 2024

Total number of voting rights and capital on January 31, 2024

        

Total number of voting rights and capital on January 31, 2024







January 31, 2024

Company announcement No. 05
 



Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes B-shares in the denomination of DKK 2 each.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, it is hereby announced that the total share capital as of today consists of nominally DKK 936,597,292 comprising a total of 468,298,646 shares, divided into 53,743,600 A shares and 414,555,046 B shares with a nominal value of DKK 2 each and a total of 1,903,982,092 voting rights.

 Nominal Value, DKKNumber of shares
A shares107,487,20053,743,600
B shares829,110,092414,555,046
Total936,597,292468,298,646



Contact information
Investor Relations  
Tobias Bjorklund
Anders Enevoldsen




Media Relations
  
Lina Danstrup



   



 

Attachment



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

 PRESS RELEASE

Incentive programs for the Executive Leadership Team, the Senior Leade...

Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees Please read the full announcement in PDF Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch